Hill-Rom (NYSE:HRC) had its target price boosted by Raymond James from $100.00 to $105.00 in a research note issued to investors on Monday. The firm currently has an outperform rating on the medical technology company’s stock.
Several other research analysts have also recently issued reports on HRC. KeyCorp increased their price objective on shares of Hill-Rom from $97.00 to $115.00 and gave the company an overweight rating in a report on Tuesday, July 17th. Zacks Investment Research cut shares of Hill-Rom from a buy rating to a hold rating in a report on Wednesday, August 1st. Northcoast Research reiterated a buy rating and issued a $104.00 price objective on shares of Hill-Rom in a report on Tuesday, July 31st. ValuEngine upgraded shares of Hill-Rom from a hold rating to a buy rating in a report on Tuesday, July 31st. Finally, Morgan Stanley increased their price objective on shares of Hill-Rom from $95.00 to $100.00 and gave the company an equal weight rating in a report on Thursday, October 11th. Five equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The stock has an average rating of Buy and a consensus price target of $100.00.
NYSE HRC traded down $0.82 on Monday, hitting $97.20. The stock had a trading volume of 148,626 shares, compared to its average volume of 696,105. Hill-Rom has a one year low of $75.68 and a one year high of $98.96. The company has a current ratio of 1.74, a quick ratio of 1.30 and a debt-to-equity ratio of 1.11. The stock has a market cap of $6.35 billion, a price-to-earnings ratio of 20.46, a price-to-earnings-growth ratio of 1.32 and a beta of 0.90.
The firm also recently announced a quarterly dividend, which will be paid on Monday, December 31st. Investors of record on Friday, December 14th will be paid a dividend of $0.20 per share. This represents a $0.80 annualized dividend and a yield of 0.82%. The ex-dividend date of this dividend is Thursday, December 13th. Hill-Rom’s dividend payout ratio is presently 16.84%.
Hedge funds have recently added to or reduced their stakes in the stock. Vigilant Capital Management LLC purchased a new stake in shares of Hill-Rom in the 2nd quarter valued at approximately $109,000. Flagship Harbor Advisors LLC purchased a new stake in shares of Hill-Rom in the 2nd quarter valued at approximately $173,000. CAPROCK Group Inc. purchased a new stake in shares of Hill-Rom in the 3rd quarter valued at approximately $211,000. Johanson Financial Advisors Inc. purchased a new stake in shares of Hill-Rom in the 3rd quarter valued at approximately $221,000. Finally, CIBC Asset Management Inc purchased a new stake in shares of Hill-Rom in the 2nd quarter valued at approximately $203,000. 80.65% of the stock is owned by institutional investors and hedge funds.
Hill-Rom Holdings, Inc operates as a medical technology company worldwide. It provides medical surgical beds, intensive care unit beds, bariatric patient beds, lifts and other devices, non-invasive therapeutic products and surfaces, and communications technologies and software solutions; and medical equipment management services, as well as sells equipment service contracts for its capital equipment.
Featured Article: Closed-End Mutual Funds (CEFs)
Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.